Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 128.50 127.00 130.00 128.50 128.50 128.50 87,737 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 199

Amryt Pharma Share Discussion Threads

Showing 5276 to 5296 of 5400 messages
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
DateSubjectAuthorDiscuss
30/11/2019
09:52
I notice from the media leaflet that gnnmartin posted that AP103 will only file Proof of Concept finding in 2023. Why so long? I thought AP103 was entering clinical trials in 2019.
chica1
28/11/2019
14:18
gnnmartin Did anyone ask about the Nasdaq? Was AP103 mentioned? Thanks
chica1
28/11/2019
13:12
I thought (or perhaps it was a guess) that the US listing was primarily aimed at letting the creditors who had got Amryt shares in the Aegerion purchase sell those shares, since (if I understood correctly) the creditors are primarily in the business of lending rather than investment in companies. Anyhow, Amryt said in answer to other questions las night that they were fully funded to complete the AP101 trial, and they expected to be EBITDA positive by the end of 2020.
gnnmartin
28/11/2019
00:40
Thank you for posting the update! Reckon we will do ok!
bazworth
28/11/2019
00:03
I've just listened to Amryt present at the Shares do near Tower Bridge. No mention of a US listing. The story sounds good without it, but those hoping for a big surge in the share price following a US listing will be disappointed.
gnnmartin
26/11/2019
23:18
radar Posts: 3,004 Price: 115.00 No Opinion Looks like Today 12:48 There’s trouble in the camp and the originators could be going it alone. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> PMSL. ROFLMAO. radar is as thick as 2 short planks. How can they "be going it alone"? There's the small matter of the 8.4m Euro's grant from the Irish Govt to develop AP103. The 3 partners, AMYT, UCD & Curran have to match that funding. AMYT are the lead partner. Where would the Branca Bunis team find 8.4m Euro's on their own? radar? PILLOCK.
papillon
25/11/2019
19:55
Cionnathagad Posts: 71 Price: 115.50 No Opinion RE: Branca Bunús..No mention of Lara Cutlar Today 14:42 Oh yeah it's the same deal.I just find it strange Amryt is not mentioned. Bronxville is right Lara Cutlar (who now works at Amryt)was one of the original scientists working on this technology since 2012 and she's not mentioned. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Why should Amryt be mentioned? Why do you find it strange, Cionnathagad? Branca Bunis is a company formed to hold the interest of UCD and it team of scientists in AP103. This company has nothing to do with Amryt. Why should Lara Cutlar be mentioned in connection with Branca Bunis? Why would you expect her to be mentioned, Cionnathagad? She's no longer part of the UCD team since she is currently employed by Amryt. It's the same for anybody who leaves their previous employment and goes to work for another employer. As far as your previous employer is concerned you become a "non" person when you go to work for someone else. The fact that UCD (Branca Bunis) and Amryt are partners in developing AP103 makes no difference. Branca Bunis and Amryt are separate company's. For instance major oil companies (for example Shell and Total) spread their risk by partnering on the development and production of a large oil discovery. However even though they may be partners on a certain project that doesn't mean that Shell would still mention a senior employee/director if they went to work for Total. That wouldn't make commercial sense.
papillon
25/11/2019
12:52
Well the UCD are stated as partners in the AP103 project, chica. It just looks like the new company is a UCD spin off and that will hold it's (and the teams) interest in AP103. They'll have to raise money to match the Irish government grant so perhaps this move makes it easier to raise their share of the costs? Again my main gripe at the moment is not with any delay in progressing AP101, or AP103, but the delay in announcing a date for the Nasdaq listing. Only then we will see a significant rerate in the AMYT sp, IMO, in the short term.
papillon
25/11/2019
12:43
Thanks👍 I don't know why Wenxin Wang is setting up a new company with his own team.
chica1
25/11/2019
12:42
chica1 25 Nov '19 - 12:24 - 5139 of 5140 0 0 0 There is nothing new there.That is what we knew back at the beginning of 2019. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> True, chica, but these trials take time to organise. It's mentioned in the RNS that it's a 3 year project. Anyway Amryt now have 2 revenue generating drugs on sale in the USA, Europe and elsewhere in the world. That revenue is evidently capable of significant growth so I presume Amryt's current focus is primarily on those 2 products and incorporating Aegerion into Amryt. Amryt has been transformed from a company with a tiny turnover into one with a circa US$150m worldwide turnover almost overnight. Patience is obviously required after such a dramatic change of direction. PS My main gripe at the moment is not any delay in progressing AP101, or AP103, but the delay in announcing a date for the Nasdaq listing.
papillon
25/11/2019
12:27
chica, read the trading update RNS issued 3 weeks ago on the 5th November for the latest on AP101. No firm date for the Phase 111 trial results was given, just that all the patients will be "enrolled in the coming months". "AP101 EASE study update: o In January 2019, following an assessment of the results of an unblinded interim efficacy analysis of its pivotal Phase 3 EASE trial for AP101 as a potential treatment for the wound-related complications of Epidermolysis Bullosa ("EB"), the Independent Data Monitoring Committee (IDMC) recommended that the trial should continue with an increase of 48 patients in the study to a total of 230 evaluable patients, in order to maintain 80% statistical power. Amryt has currently enrolled 203 patients in the study and is on track to be fully enrolled in the coming months. o Following an assessment in February 2019 by the EASE trial's IDMC of pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older), Amryt is now enrolling infants and children with EB between the ages of 21 days to 4 years of age into the trial o In October 2019, AP101 received Fast Track Designation from the FDA (Food and Drug Administration). Fast Track designation enables more frequent communication with the FDA and may allow for further benefit from FDA accelerated programmes such as priority review and/or rolling review." https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Trading-Update/81064548 Regarding AP103, that RNS issued 2 months ago, says that their are 3 partners in the "consortium". Amryt, UCD and DEBRA Ireland and that Amryt is the lead partner which must mean that Amryt has the largest stake in AP103, but what percentage that is isn't mentioned. 40%,50%, or 80%? We just don't know because we haven't been told!
papillon
25/11/2019
12:24
There is nothing new there.That is what we knew back at the beginning of 2019.
chica1
25/11/2019
11:32
I wonder what all this means for Amryt.I think February is the last time we have heard about AP103 from Amryt.Why aren't we in clinical trials? I was reading over the weekend and I think AP101 is 1 1/2 behind schedule.
chica1
24/11/2019
13:18
I've copied these posts from another thread: spuddymadrid 24 Nov '19 - 09:25 - 10 of 12 0 0 0 hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ spuddymadrid 24 Nov '19 - 09:28 - 11 of 12 0 0 0 2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide. EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease. The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou. papillon 24 Nov '19 - 13:10 - 12 of 12 Edit 0 0 0 hTTps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Grant-Funding-from-Irish-Governme/78851836 "The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".
papillon
24/11/2019
13:10
hTTps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Grant-Funding-from-Irish-Governme/78851836 "The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".
papillon
24/11/2019
09:28
2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide. EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease. The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou.
spuddymadrid
24/11/2019
09:25
hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/
spuddymadrid
21/11/2019
12:19
Where's that Nasdaq listing date? The share price needs it.
papillon
15/11/2019
19:33
"Cheers & have a splendiforous weekend!!" And let me wish the same for you, bazworth. I could do with an over £20k profit on my modest AMYT investment. Bring it on and the sooner the better! Will it happen? I can't predict share prices, but fingers crossed it does!
papillon
15/11/2019
18:48
My eyes are firmly closed! Please text a voice message to me when we get there. My meagre stipend in retirement could do with a good shove!! Cheers & have a splendiforous weekend!!
bazworth
15/11/2019
18:34
Another two 25k trades, bazworth, both @ 118p reported after the market closed at 4:35pm. Probably reporting delayed by an hour since there was no after close auction announced. The 118p price dictates they were both sells, but they could have been a rollover because the time difference between the two trades was just 13 seconds. Whatever they were that brings the number of trades today to 22. "Just wait till we’re @ £5 a share!!" When will that be, bazworth? Next week, next month, next year? Have another look into your crystal ball, bazworth, as I need more clarity! Hopefully I don't have to wait too long for that £5 per share as I'm getting on a bit! :-)
papillon
Chat Pages: 216  215  214  213  212  211  210  209  208  207  206  205  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200223 21:11:47